恩替卡韦治疗对慢性乙型肝炎患者特异性细胞免疫功能的影响及其与HBeAg血清学转换的关系

The effect of entecavir treatment on HBV-specific immunity in patient with chronic hepatitis B and its relationship to HBeAg sero-conversion

目的探讨恩替卡韦治疗对慢性乙型肝炎患者特异性细胞免疫功能的影响及其与HBeAg血清学转换的关系。方法慢乙肝患者恩替卡韦治疗前后不同时间点检测转氨酶（ALT）、HBVDNA和HBeAg表达量，同期[^3H]T-dR掺入法测定外周血特异性淋巴细胞增殖反应，采用ELISA测定HBV抗原特异性IFN-γ表达水平。结果与治疗前相比较，治疗一个月后的患者ALT、HBVDNA和HBeAg水平显著下降，而特异性T淋巴细胞增殖反应和特异性IFN-γ表达水平显著增高。结论恩替卡韦治疗过程中，伴随患者体内HBV复制水平的下降，患者HBV特异性细胞免疫功能增高。特异性免疫的增强与HBeAg血清学转换存在相关性。

Objective To investigate the effect of Entecavir treatment on HBV-specific immunity in patient with chronic hepatitis B and its relationship to HBeAg sero-conversion. Methods Serum aminotransferase （ALT）, HBV DNA and HBeAg were monitored before the after entecavir treatment. At the same time point, HBV- specific T ceil proliferation was determined by [^3H] T-dR incorporation assay, while HBV-specific IFN-γ secretion was measured by ELISA. Result The level of HBV DNA and ALT was significantly decreased after entecavir treatment. Same is the titer of HBeAg. In addition, HBeAg sere-conversion was observed in some of them, in whom the HBV-specific T cell proliferation and IFN-γ production were significantly increased. Conclusion Entecavir treatment resuIted in increased HBV-specific immunity along with the inhibition of HBV replication.